Literature DB >> 30709955

Utility of Magnetic Resonance Imaging in Diagnosis and Monitoring Enthesitis in Patients with Spondyloarthritis: An OMERACT Systematic Literature Review.

Ashish J Mathew1,2, Simon Krabbe3,4, Richard Kirubakaran3,4, Andrew J Barr3,4, Philip G Conaghan3,4, Paul Bird3,4, Mikkel Østergaard3,4.   

Abstract

OBJECTIVE: A systematic literature review was performed to document published magnetic resonance imaging (MRI) lesion definitions and scoring systems for enthesitis in spondyloarthritis (SpA).
METHODS: PubMed, Embase, and Cochrane Library databases were searched for original publications involving adult patients with SpA undergoing MRI of axial/peripheral joints. Selected articles were assessed for quality using a standardized assessment tool and metric indices.
RESULTS: Considering the heterogeneous design, quality, and outcome measures of studies, statistical data pooling was considered inappropriate. A qualitative narrative of results was undertaken based on study designs.
CONCLUSION: Lack of a comprehensive, validated score warrants additional research to develop an MRI enthesitis scoring system. PROSPERO registration number: CRD42018090537.

Entities:  

Keywords:  ENTHESOPATHY; INFLAMMATION; MAGNETIC RESONANCE IMAGING; OMERACT; SPONDYLOARTHROPATHY

Mesh:

Year:  2019        PMID: 30709955     DOI: 10.3899/jrheum.181083

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  2 in total

1.  Atlas of the OMERACT Heel Enthesitis MRI Scoring System (HEMRIS).

Authors:  Ashish J Mathew; Simon Krabbe; Iris Eshed; Robert Gw Lambert; Jean-Denis Laredo; Walter P Maksymowych; Frederique Gandjbakhch; Yasser Emad; Maria Simona Stoenoiu; Violaine Foltz; Paul Bird; Philippe Carron; Joel Paschke; Philip G Conaghan; Susanne J Pedersen; Daniel Glinatsi; Mikkel Østergaard
Journal:  RMD Open       Date:  2020-02-11

2.  Enthesitis in psoriatic arthritis (Part 2): imaging.

Authors:  Gurjit S Kaeley
Journal:  Rheumatology (Oxford)       Date:  2020-03-01       Impact factor: 7.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.